Healthcare tech company Privia Health Group (NASDAQ: PRVA) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 21.4% year on year to $632.6 million. Its non-GAAP profit of $0.19 per share was 22.2% below analysts’ consensus estimates.

Is now the time to buy PRVA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Privia Health’s second quarter results were met with a negative market reaction as investors digested the company’s strong revenue growth alongside a material shortfall in non-GAAP profit relative to Wall Street expectations. Management attributed the top-line performance to robust provider signings and expanded value-based attributed lives, noting that implemented provider growth of 10.1% and value-based attributed lives growth of 19.2% drove overall practice collections. CEO Parth Mehrotra pointed to “strong new provider signings across all our markets,” while CFO David Mountcastle highlighted operational leverage and ongoing investments.

Looking ahead, Privia Health’s guidance is anchored by continued expansion in both implemented providers and attributed lives, as well as the scaling of AI initiatives to drive efficiency and margin improvement. Management expects operating leverage and technology-driven productivity gains to support margin expansion over the next several years. Mountcastle stated the company is “confident that our integrated model, combining medical groups, risk-bearing entities and tech and services platforms will continue to drive sustainable growth and profitability for years to come.”

Key Insights from Management’s Remarks

Management cited provider network growth, efficiency improvements, and value-based care expansion as key drivers of the quarter, while margin pressures and cautious guidance for the second half weighed on earnings.

• Provider network expansion: Privia Health’s growth was propelled by strong provider signings across all markets, leading to a 10.1% increase in implemented providers and improved visibility into future performance. The entry into New Jersey with Urology Group of Bergen County marked the company’s 25th state.
• Value-based care momentum: Management highlighted robust growth in attributed lives within value-based contracts, with commercial attributed lives rising 11.7% and Medicare program attribution up 55%. This diversification reduces risk exposure to any single payer segment.
• Operational leverage and AI deployment: Ongoing deployment of artificial intelligence applications was credited with supporting efficiency gains and margin improvement. Mountcastle linked margin expansion to “our ability to deploy these applications and seeing if things can be done better, faster, cheaper.”
• Recent acquisitions integrated: The company reported successful integration of recent deals, including Evolent’s Care Partners and IMS in Arizona, which contributed to geographic diversification and expanded service offerings. Management cited Arizona as a high-potential market and described additional tuck-in acquisition opportunities.
• CMS policy changes and cash flow timing: Proposed changes to the Medicare Shared Savings Program (MSSP) may delay settlement timing for value-based payments, but management expressed confidence in eventual payment receipt. Mehrotra noted, “We don’t see any issues in receiving the money,” despite the potential for a year-end cash flow shift.

Drivers of Future Performance

Privia Health’s outlook is driven by continued provider network expansion, AI-enabled operating leverage, and continued growth in value-based contracts, but management flagged some conservatism in second-half projections.

• AI-driven margin expansion: Management believes ongoing investment in AI applications—such as workflow automation, clinical support, and revenue cycle management—will boost productivity and support higher EBITDA margins relative to care margin. The company aims to reach the high end of its long-term margin target through these efficiency gains.
• Conservative second-half outlook: While provider and attributed lives growth remains strong, Mehrotra described the company’s second-half revenue outlook as "prudent" and "conservative," citing no material headwinds but a preference for caution given historical seasonality and the timing of provider onboarding.
• Value-based diversification: The company continues to expand its footprint in value-based care, leveraging a diversified mix of commercial, Medicare Advantage, Medicaid, and MSSP contracts. Management expects this strategy to provide resilience against payer-specific fluctuations and regulatory changes.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will watch (1) the pace of AI-enabled efficiency gains and their impact on operating margins, (2) progress in onboarding new providers and further expansion into new states, and (3) updates on value-based contract performance and any regulatory changes impacting cash flow timing. Execution on recent acquisitions and the development of local market density will also be critical markers of sustainable growth.

Privia Health currently trades at $21.67, down from $23.96 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.